PCSK9 inhibitors block PCSK9 proteins from breaking down your LDL receptors. The result is that more of your LDL receptors work. These active LDL receptors can then reduce your LDL cholesterol more efficiently.

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme encoded by the PCSK9 gene in humans on chromosome 1. [5] It is the 9th member of the proprotein convertase family of proteins that activate other proteins. [6] Similar genes are found across many species.

Sep 1, 2021 · PCSK9 inhibitors suppress the PCSK9 enzyme expressed by the gene. Here are common PCSK9 inhibitors and what the research says about their effectiveness.

Elevated levels of circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) are associated with increased low-density lipoprotein (LDL) and worse cardiovascular outcomes. Antibodies to PCSK9 have been approved by regulatory agencies for the treatment of individuals with inadequately treated levels of LDL-cholesterol (LDL-C).

What are PCSK9 inhibitors? Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme that binds to low-density lipoprotein receptors (LDL receptors), which stops LDL being removed from the blood, leading to an increase in blood levels of LDL.

Nov 20, 2015 · Proprotein convertase subtilisin/kexin type 9 serine protease (PCSK9) plays an important role in cholesterol metabolism by regulating LDL receptor degradation. Shortly after its discovery in 2001, the gene encoding PCSK9 was implicated in …

Mar 30, 2025 · PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) is a Protein Coding gene. Diseases associated with PCSK9 include Hypercholesterolemia, Familial, 3 and Homozygous Familial Hypercholesterolemia. Among its related pathways are Plasma lipoprotein assembly, remodeling, and clearance and Cholesterol metabolism.

Apr 11, 2025 · AZD0780, an investigational once-daily oral PCSK9 inhibitor for patients not currently reaching their LDL-C lowering goal despite standard lipid-lowering therapies, led to a 50.7% reduction in LDL-C (95% CI, -59.0% to -42.4%, P < .001) when taken at 30 mg daily in the PURSUIT trial.This efficacy data was observed regardless of whether participants received …

Aug 20, 2023 · PCSK9 is a protein that plays a pivotal role in cholesterol homeostasis. It acts primarily by binding to the LDL receptors (LDLRs) on the surface of liver cells. Normally, LDLRs capture LDL particles from the bloodstream and bring them into the liver cell, where they are broken down by lysosomes in a process called Endocytosis ( Fig-1 ).

PCSK9 inhibitors (or PCSK9i) are a new type of medicine for lowering cholesterol in the blood. Discover how PCSK9 inhibitors work, who should take them and possible side effects.